STOCK TITAN

Guardant Health - GH STOCK NEWS

Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.

Overview of Guardant Health

Guardant Health is a precision oncology company that specializes in liquid biopsy tests and advanced genomic diagnostics. As a leader in the field of liquid biopsy and cancer diagnostics, the company has developed innovative, non-invasive tools that enable oncologists to access and sequence tumor DNA, thereby providing critical insights into cancer biology. Its robust suite of tests is designed for various clinical applications including treatment selection, detection of minimal residual disease, and broader gene panel analyses for immuno-oncology research.

Core Business Areas

Guardant Health operates at the intersection of advanced technology and medical science to revolutionize the way cancer is diagnosed and monitored. The company offers a comprehensive range of services, including:

  • Liquid Biopsy Testing: Non-invasive blood tests that analyze circulating tumor DNA to inform treatment decisions and monitor disease progression.
  • Companion Diagnostics: FDA-approved assays that help guide targeted cancer therapies ensuring that patients receive tailored treatment options.
  • Molecular Residual Disease (MRD) Testing: Tumor-agnostic tests designed to detect molecular evidence of cancer recurrence, enhancing post-treatment monitoring.
  • Research and Development Services: End-to-end support in regulatory consultancy and clinical trial referral, aiding clinical research and collaboration.

Market Position and Industry Impact

Guardant Health has established a significant presence in the precision oncology landscape by harnessing advanced data analytics and genomics. Its liquid biopsy solutions provide a safer, more efficient alternative to traditional tissue biopsies, thus facilitating faster and more accurate diagnostic processes. The company is also known for contributing to the broadening of cancer data acquisition, a crucial factor in driving discovery and innovation in cancer treatment and research. The integration of real-world data with artificial intelligence analytics has positioned Guardant Health as a valuable partner in both clinical and research settings, offering insights that have the potential to influence treatment protocols and clinical guidelines.

Operational Excellence and Scientific Rigor

At the core of Guardant Health's operations is a rigorous dedication to scientific accuracy and clinical validation. Every test is backed by detailed research and validated methodologies that ensure precise outcomes. The company emphasizes a strong ethical foundation by ensuring that its products are developed with a focus on patient safety and diagnostic integrity. This approach not only enhances trust among clinicians but also positions the firm as an authoritative voice in the field of oncology diagnostics.

Competitive Landscape and Differentiation

In a competitive market where several companies vie to innovate in cancer diagnostics, Guardant Health differentiates itself through its comprehensive approach to liquid biopsy technology. The company’s ability to offer a spectrum of tests across various stages of cancer care—ranging from early detection to monitoring minimal residual disease—illustrates its commitment to improving patient outcomes. Additionally, its successful legal defenses and insistence on data accuracy further underscore its focus on maintaining high standards across all areas of operation.

Commitment to Innovation and Data-Driven Discoveries

Guardant Health’s approach is deeply rooted in the belief that conquering cancer is as much a data problem as it is a medical challenge. Through the creation and application of advanced sequencing techniques and comprehensive data analytics, the company is continuously expanding its product offerings and clinical insights. This data-centric approach not only fuels ongoing innovation but also supports extensive research collaborations that are pivotal for furthering advancements in cancer care.

Conclusion

Overall, Guardant Health represents a forward-thinking enterprise in the realm of precision oncology, offering groundbreaking diagnostic solutions that bridge the gap between advanced technology and clinical practice. Its commitment to non-invasive testing, rigorous validation, and comprehensive clinical services helps demystify the complexities of cancer diagnostics, making it an essential component of modern medical research and patient care.

Rhea-AI Summary

Guardant Health reported Q2 2020 revenue of $66.3 million, up 23% year-over-year, driven by precision oncology revenue growth of 21% to $51.0 million. Development services revenue rose 29% to $15.3 million. The company conducted 13,694 clinical tests and 2,805 biopharmaceutical tests, marking a 15% increase and a 47% decrease, respectively. Guardant's gross profit increased to $43.9 million with a 66% gross margin. However, operating expenses surged 88% to $98.5 million, resulting in a net loss of $54.6 million, up from $11.6 million the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
-
Rhea-AI Summary

Guardant Health has partnered with Radius Health to seek regulatory approval for Guardant360® as a companion diagnostic for elacestrant, a treatment for advanced ER-positive, HER2-negative breast cancer resistant to CDK4/6 inhibitors. The ongoing EMERALD phase III trial is assessing elacestrant's efficacy compared to standard endocrine therapy, particularly in patients with ESR1 mutations identified by the Guardant360 test. This collaboration enhances the utility of Guardant360 in guiding treatment decisions and addresses the growing demand for liquid biopsy solutions in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) will announce its Q2 2020 financial results on August 6, 2020, following market close. A conference call will be held at 1:30 PM PT to discuss these results, accessible via the company’s website. Guardant Health is recognized for its innovative blood tests and advanced analytics aimed at improving cancer patient outcomes and reducing healthcare costs. The company has developed tests like Guardant360 and GuardantOMNI® to support advanced cancer care and is evolving its LUNAR program for early-stage cancer detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
Rhea-AI Summary

Guardant Health (Nasdaq: GH) announced a collaboration with Janssen Biotech to obtain regulatory approval for the Guardant360 CDx as a companion diagnostic for amivantamab, targeting non-small cell lung cancer (NSCLC) treatment in the U.S., Canada, Japan, and Europe. Guardant360, a liquid biopsy test, analyzes 74 genes to enhance genotyping rates and personalized therapy for cancer patients. The test is already covered by Medicare for most advanced solid tumors, aiding in treatment decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
-
Rhea-AI Summary

Guardant Health, a precision oncology company, launched the GuardantINFORM platform to enhance cancer drug development. This platform integrates clinical-genomic data from over 100,000 liquid biopsy tests, aiming to provide insights into tumor evolution and treatment resistance. Key applications include targeted drug development, clinical trial optimization, and post-marketing studies. The platform presents a significant opportunity for researchers in precision oncology, focusing on advanced solid tumors. However, Guardant Health warns that the platform's future potential is subject to various risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
-
Rhea-AI Summary

Guardant Health (Nasdaq: GH) presented new data at the AACR Virtual Annual Meeting II, demonstrating that its LUNAR-2 liquid biopsy achieves 90% sensitivity and 94% specificity in detecting early-stage colorectal cancer (CRC). Further analysis showed a specificity of 99% among controls negative for CRC by colonoscopy. These results highlight the potential of LUNAR-2 to enhance cancer screening rates, especially amid COVID-19 challenges. The assay is currently under evaluation in the ECLIPSE trial for average-risk adults.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
none
Rhea-AI Summary

Guardant Health (Nasdaq: GH) has appointed Vijaya Gadde to its Board of Directors, enhancing its leadership team. Gadde, currently Chief Legal Officer at Twitter, brings extensive experience in public policy and technology management. President AmirAli Talasaz emphasized her potential to guide the company's growth in precision oncology. Gadde expressed enthusiasm for contributing to Guardant's mission of improving cancer care through innovative data solutions, particularly in advanced cancer and early detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
management
-
Rhea-AI Summary

Guardant Health, a precision oncology company, announced the completion of a public offering of 13,225,000 shares of common stock at $84.00 per share, raising approximately $362.3 million in gross proceeds. Of these shares, 4,312,500 were sold by Guardant Health, while 8,912,500 were sold by SoftBank Investment Advisers. The net proceeds will primarily support corporate purposes, including working capital, sales, marketing, and capital expenditures. J.P. Morgan acted as the sole book-running manager for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Summary

Guardant Health has announced a public offering of 11,500,000 shares of its common stock priced at $84.00 per share, raising approximately $315 million before deductions. The offering was increased from an initial size of 10 million shares, with a 30-day option for underwriters to buy an additional 1,725,000 shares. The net proceeds will be used for general corporate purposes, including working capital and sales activities. The offering is expected to close on June 4, 2020, pending customary conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rhea-AI Summary

Guardant Health has announced a proposed public offering of 10,000,000 shares of its common stock, with 3,000,000 shares being offered by the company and 7,000,000 shares by SoftBank Investment Advisers. An additional 1,500,000 shares may be available through an underwriter's option. The offering aims to raise funds primarily for general corporate purposes, including working capital and marketing activities. The offering is subject to market conditions and will not yield proceeds to Guardant Health from SoftBank's shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags

FAQ

What is the current stock price of Guardant Health (GH)?

The current stock price of Guardant Health (GH) is $40.58 as of April 4, 2025.

What is the market cap of Guardant Health (GH)?

The market cap of Guardant Health (GH) is approximately 5.0B.

What is Guardant Health's primary business focus?

Guardant Health specializes in developing and offering liquid biopsy tests for cancer diagnostics, utilizing advanced genomic testing and data analytics to support treatment selection and disease monitoring.

How do Guardant Health's liquid biopsy tests work?

The tests use a non-invasive method to analyze circulating tumor DNA from blood samples, providing oncologists with critical information that can guide treatment decisions and monitor disease progression.

What types of diagnostic assays does Guardant Health offer?

Guardant Health provides a range of assays including companion diagnostics for targeted therapies, molecular residual disease tests for post-treatment monitoring, and extensive gene panels for immuno-oncology research.

How does Guardant Health differentiate itself from competitors?

The company differentiates itself through a comprehensive portfolio of liquid biopsy tests, a strong commitment to scientific rigor, and successful legal defenses that validate its clinical and technological approaches.

What role does data analytics play in Guardant Health’s operations?

Data analytics is fundamental to its approach, enabling the company to harness vast amounts of cancer-related data to drive insights, support clinical decision-making, and fuel ongoing innovations in diagnostic testing.

Who are the primary users of Guardant Health's products?

Guardant Health's products are widely used by oncologists and clinical researchers, serving patients across all cancer stages through both diagnostic support and research collaboration.

What are the benefits of using a liquid biopsy?

Liquid biopsies offer a less invasive alternative to traditional tissue biopsies, reducing patient risk while providing rapid, accurate insights into tumor genetics and disease progression.

How does Guardant Health contribute to advancements in cancer research?

By integrating comprehensive cancer data acquisition with advanced genomic analysis, Guardant Health supports broad research collaborations that drive the discovery of new biomarkers and innovative therapeutic approaches.
Guardant Health

Nasdaq:GH

GH Rankings

GH Stock Data

5.01B
117.49M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO